FDA expands use of Actemra to include polyarticular JIA

Genentech received approval from the Food and Drug Administration to market Actemra, or tocilizumab, for children age 2 and older with active polyarticular juvenile idiopathic arthritis. The drug, a humanized interleukin-6 receptor antagonist, can be given alone or with methotrexate. The approval was based on data from a late-stage trial showing that the drug improved symptoms in children with the condition.

View Full Article in:

Medscape (free registration) · BioPharm International online

Published in Brief:

SmartBrief Job Listings for Education

Job Title Company Location
Senior Researcher (8194)
American Institute for Researcher
Washington, DC
Technical Assistance Associate (8330)
American Institute for Researcher
Chicago, IL
Technical Assistance Consultant (8336)
Am
Chicago, IL
Director of Professional Services
Engaging Schools, Inc.
Cambridge, MA
Principal at Timberland Charter Academy
Timberland Charter Academy
Muskegon, MI